CA
NZ
UK
AU
IND
US
SPCX stock fell to an all-time low of $132.15, dipping below its $135 IPO price, as Elon Musk's aerospace company declined for a fourth straight session following its historic Wall Street debut last month. The initial post-IPO enthusiasm that lifted the stock in its …
The safety data itself was genuinely encouraging on its own terms. All side effects observed during the initial dosing cycles were fully manageable with standard supportive care, resulting in zero treatment-related serious adverse events or Grade 3 or higher toxicities. For a combination therapy …
Eli Lilly and Company (NYSE: LLY) announced a definitive agreement on July 16, 2026, to acquire AtaiBeckley Inc. (NASDAQ: ATAI) in a transaction valued at up to approximately $3.8 billion, marking one of the most significant moves by a large-cap pharmaceutical company into the …
Immuron (NASDAQ: IMRN) reported that unaudited global Travelan sales for fiscal year 2026 rose 6% to AUD$7.7 million, representing the fourth consecutive quarter of year-over-year growth for its flagship product — an important commercial milestone for a small-cap biotech company establishing consistent revenue growth …
Kairos Pharma (NASDAQ: KAPA) disclosed preliminary safety results from its Phase 1 clinical study evaluating ENV-105 in combination with osimertinib for patients with advanced EGFR-mutated non-small cell lung cancer, marking a key development for a program targeting one of oncology's most clinically pressing challenges: …
Lakewood-Amedex Biotherapeutics (OTC: LABT) reported encouraging preclinical safety results for its antimicrobial Nu-3 gel, establishing the foundational safety profile needed to advance into its anticipated Phase 2a clinical trial in patients with infected diabetic foot ulcers — a significant and growing area of unmet …
Galmed Pharmaceuticals (NASDAQ: GLMD) established a strategic partnership with Barcode Nanotech to engineer a novel lipid nanoparticle delivery system for Aramchol, the company's proprietary stearoyl-CoA desaturase 1 (SCD1) inhibitor, with the initiative focused on leveraging Barcode's specialized delivery platform to enhance Aramchol's therapeutic reach …
Virax Biolabs (NASDAQ: VRAX) issued a corporate update detailing a meaningfully strengthened financial position, commercial progress, and regulatory compliance restoration that collectively represent a significant improvement in the company's operational stability and near-term commercial trajectory.
Arbutus Biopharma (NASDAQ: ABUS) initiated fresh patent litigation in Canada and before the Unified Patent Court against Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), targeting the mRNA-LNP technologies used in their COVID-19 vaccines — continuing a pattern of IP enforcement that has already produced …
Two developments released in close proximity have transformed the investment and regulatory landscape for psychedelic medicine: the US Food and Drug Administration's publication of its final guidance on psychedelic drug clinical investigations, and Eli Lilly and Company's (NYSE: LLY) definitive agreement to acquire AtaiBeckley …
Please wait processing your request...